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S U M M A R Y
Surgery for drug-resistant tuberculosis has been shown to be safe and effective, with similar level of
mortalities associated with surgical intervention observed with that for lung cancer. While surgery has
been an option to treat TB in the pre-antibiotic era, it is now increasingly used to treat complications of
pulmonary TB, particularly in patients with drug-resistant TB who do not respond to medical treatment.
The two most frequent indications for lung resection in drug- resistant TB, are i) failed medical treatment
with persistent sputum positivity or ii) patients who have had medical treatment and are sputum
negative, but with persistent localized cavitary disease or bronchiectasis. Massive hemoptysis is a
potentially life-threatening complication of TB. Lung resection is potentially curative in patients with
massive hemoptysis and cavitary or bronchiectatic disease. Bronchial artery embolization in these
patients has a high success rate but bears also the risk of recurrence. Lung resection can be safely
undertaken in selected patients with HIV co-infection and pulmonary complications of TB. Ambulatory
drainage is a novel, safe, affordable and effective method of draining a chronic TB associated empyema
thoracis. We review here the current surgical treatment of the complications of pulmonary TB and
discuss the experience from the Durban Cardiothoracic Surgery Unit for the surgical treatment of
patients with complicated pulmonary TB.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Prior to the availability of anti-tuberculosis (TB) drugs, surgery
was the only treatment option for the treatment of TB. However,
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).became the standard therapy for TB. Yet the battle against TB and
the progress of the past several decades in TB treatment is at risk to
be lost with the emergence of drug-resistant TB (DR-TB). Lung
resection is increasingly being explored as a treatment option for
patients with DR-TB who exhibit poor results in the antibiotic
treatment regimens, or are in need for prolonged treatment with
second line drugs or injectable drugs. This is particularly true for
patients with extensively drug resistant TB (XDR-TB). Patients with
DR-TB exhibiting lung destruction exhibit similar risks of surgery
as compared to patients undergoing lung resection for bronchial
carcinoma.1,2 It is also recommended that lung resection should be
the primary modality of treatment and not bronchial arteryciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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sis with localized cavitary lung disease. We discuss in this review
the current literature in the ﬁeld of surgical treatment for TB and
discuss our experience (i.e. the Durban Cardiothoracic surgical
team) concerning the management of patients undergoing lung
resection. We also discuss a novel method of managing chronic TB
associated empyema, not suitable for decortication.
The results of medical treatment particularly for XDR-TB are
dismal with cure rates of 7% at 2 years and 5% at 5 years and
mortality of 46% at 2 years and 73% at 5 years.3 Surgery for
pulmonary TB gave rise to the discipline of Thoracic Surgery. It is
now more increasingly being investigated as treatment for drug-
resistant tuberculosis in the presence of lung destruction.1,2,4
Thoracic surgery has evolved from drainage of empyema through
bronze cannula and ‘collapse therapy’ to the current status where
intricate, extensive lung and chest wall resections can be
undertaken for various lung pathologies. It can be broadly
categorised into diagnostic interventions and therapeutic inter-
ventions. In the developed world, the majority of lung resections
are for bronchial carcinoma. However, in the developing world, TB
remains the main indication for lung resection.
2. Evolution of Surgical Treatment of Pulmonary TB
The early period for the surgical treatment of TB is reﬂected in
the three decades of the nineteenth century, when collapse
therapy was performed by open surgical pneumothorax with a
high rate of asphyxia–associated death.5 Induced pneumothorax
was widely practiced in the pre-antibiotic era in more than
100,000 patients with pulmonary TB over a period of quarter
century starting in 1882 until the early 20th century.6 Lobectomy,
open drainage, and instillation of antiseptics into cavities was tried
in the beginning of 20th century. Improved collapse therapy and
increased quality of thoracic surgery took place from 1930 onwards
along with the advent of better diagnostic procedures with
bronchoscopy, improvement in X-ray technique and development
of bronchospirometry. Initially surgical intervention in Pulmonary
TB was not viewed positively due to the high risks associated with
TB (disease). Nevertheless, pneumonectomies, lobectomies, thor-
acoplasty (removal of ribs to collapse the chest wall) and
pleurolytic operations were performed in selected patients with
some success. Throughout 1950s, thousands of Pulmonary TB
patients received surgical resection as adjunctive therapy to
Streptomycin therapy.7
3. Lung Resection in TB
The classic indications for lung resection in TB are recurrent
chest infections, recurrent minor hemoptysis, massive hemoptysis,
DR-TB, any complication of TB (empyema thoracis, broncho-pleural
ﬁstula) persistent sputum positivity with irreversible pulmonary
destruction: cavitation and/or bronchiectasis and suspicion of
malignancy.8 Surgery usually entails either lobectomy, bilobect-
omy, pneumonectomy or staged lobectomies for localized bilateral
disease. Wedge or segmental resections are usually avoided due to
the increased risk of a bronchopleural ﬁstula. Occasionally, it is
performed in the case of upper lobar disease warranting upper
lobectomy as well as apical lower segmental disease, given that the
basal segments are adequate to ﬁll the pleural space.
4. Surgery for DR-TB
Renewed interest in surgical intervention in TB was driven by
increasing failures in TB chemotherapy, i.e. with the advent of
MDR-TB, the emergence of XDR-TB and TDR-TB that are resistant
to most drugs in use. Surgery for DR-TB has been shown to be safeand effective,9 with operative mortalities similar to surgery for
lung cancer.1 We have also shown that surgery for XDR-TB and
massive hemoptysis is safe.2,10 There are two speciﬁc indications
for lung resection in DR-TB, i.e. failed medical treatment with
persistent sputum positivity and patients who have had medical
treatment and are sputum negative, but have localized cavitary
disease or bronchiectasis.11 These are potential ‘safe-havens’ for
mycobacteria that give rise to future relapses. Mycobacteria have
developed mechanisms to overcome the host immune surveil-
lance.12 Little is known about this in the human lung, a potential
area for future investigation. The ﬁrst report on lung resection from
our center reviewed 23 patients of MDR-TB including 10 sputum
culture positive over a 5-year period between 1996-2000.13
Pneumonectomy was performed in 17 patients and lobectomy in
6 individuals with no operative or postoperative  mortality. Major
complications developed in 4 patients (17.4%): 2 had post-pneumo-
nectomy empyema and 2 underwent rethoracotomy for bleeding. The
outcome was excellent with a cure rate of 95.6% (only 1 out of
10 remained sputum positive at the end of the follow-up period of the
study). The Durban cardiothoracic surgical team suggested pulmo-
nary resection as an important adjunct to medical therapy in carefully
selected patients with localized disease with adequate pulmonary
reserve, for patients who have multiple previous relapses, or for
patients whose sputum remains positive after 4 to 6 months of
appropriate medical treatment. In the authors’ view, surgery offers
high cure rates with acceptable morbidity and mortality.
The predominance of left-sided resection in the ﬁrst series and
other published reports suggested that the more horizontal course
of the narrower left main bronchus and the smaller peribronchial
space contribute to the left lung being more commonly involved.
Preoperative sputum positivity is a recognized risk factor for post-
pneumonectomy empyema, which developed in 2 of our patients,
both of whom were sputum positive preoperatively. One of these
patients was HIV positive with a preoperative empyema. Bronchial
stump reinforcement has been advocated to prevent the postop-
erative development of bronchopleural ﬁstula.
A subsequent report from our centre ﬁrst reported surgical
experience in XDR-TB in Africa reviewing 11 patients with
conﬁrmed XDR-TB referred for surgical resection between Jan
2007 to June 2010, due to failure of a treatment regimen
appropriate for XDR-TB, complications of TB sequelae such as
hemoptysis or recurrent chest infections.2 Among these, 6 were
excluded from surgical intervention due to bilateral, extensive
cavitatory disease. Five patients were surgically treated, two with
pneumonectomies and three with upper lobectomies with no
perioperative mortality or major morbidity with cure in all these
patients. One of these ﬁve was also HIV infected and two others
were health care workers. The Durban cardiothoracic surgical team
has stressed the necessity of appropriately selecting candidates
with DR-TB for surgical intervention and in particular the ones
with persistent sputum positivity with second line chemotherapy
based on drug susceptibility.
A different study, performed in Georgia, showed results from
MDR-TB and adjunctive surgical resection: resection was per-
formed in 37 MDR/XDR-TB patients with 5 new cases and 32 of
retreatment cases with favourable outcome in 29 out of 37 (78%).
These favorable data suggested adjunct surgical treatment in the
management of M/XDR-TB.14
A systematic review and meta-analysis of adjunctive pulmo-
nary resection for patients with MDR-TB with the inclusion of
15 studies (a total sample size of 949) showed the overall cure rate
as high as 84%.15 Aggressive use of resectional lung surgery was
practiced at the National Jewish Medical and Research Center
(NJMRC) which is a specialized hospital for DR-TB care. The report
covered the period 1984 to 1998 and described the clinical
management and outcome of 205 MDR-TB cases, of which
Figure 1. Massive Hemoptysis. A High Resolution CT Scan of a patient with massive
hemoptysis, showing middle lobe bronchiectasis and lower lobe cavitation.
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least one resectional procedure.16 Of 122 patients who had
resection performed in one lung, 63 had a pneumonectomy,
and 59 had one or more lobectomies. Of eight patients who had
resection performed in both lungs, ﬁve had one or more
lobectomies, and three had a pneumonectomy in combination
with contralateral lobectomy. One additional patient had a
thoracoplasty, and another underwent pneumoperitoneum thera-
py. The progressive use of surgery reﬂected the evolution of their
experience in which surgical intervention associated with low
complication rates. The favorable data consolidated the notion that
surgical intervention will lead to favorable outcomes in individuals
undergoing surgery.
Our approach to lung resections for DR-TB has been to resect all
diseased lungs similar to surgery for lung cancer. Lung resection
includes all bronchiectatic and cavitary (TB) disease, as well as
areas of nodularity: these may be micro abscesses containing
mycobacteria. Ongoing studies are being undertaken to assess
whether we have achieved the clinical objective of lung resection
in DR-TB: Mtb culture conversion and prevention of future
relapses. We work in close collaboration with the pulmonary
physicians in managing these patients.
5. Surgery for Massive Hemoptysis
Lung resection has to be undertaken as an emergency only in
the case of massive hemoptysis with cavitary lung disease or
bronchiectasis. Patients with massive hemoptysis are referred
directly to us or by the pulmonary physicians. While TB may
present with pulmonary disease and symptoms, its effect and
presence is beyond the lungs and should be regarded as a systemic/
lymphatic disease.17 Surgery addresses only the ‘gross’, macro-
scopic disease, and not the systemic or disease beyond the resected
lung. Therefore, most patients with pulmonary TB should undergo
a full course of TB treatment. The Durban cardiothoracic surgical
team advises surgery for patients who have completed at least
6 months of TB treatment prior to surgery. Various durations of
treatment, from 0.6 months to up to 240 months,18 have been
published in the literature and there is no consensus on this topic.
Patients with massive hemoptysis along with cavitary lung disease
have had little or no anti-TB treatment. Bronchial artery
embolization has been shown to be less effective in cavitary lung
disease and bronchiectasis; it has shown high recurrence rates of
hemoptysis.19 The success rate of bronchial artery embolization for
massive hemoptysis has been over 90%.10 But these data are
collected from a heterogeneous population including infections
other than TB, cystic ﬁbrosis, malignancies and more importantly
for bronchiectasis, not restricted to cavitary lung disease.
A publication from Turkey reported surgical management of
TB-related hemoptysis in 59 patients with 21 performed in the
context of emergency procedures for massive hemoptysis
(>600 ml/d), in 24 over ﬁrst 2 days with major hemoptysis
(200-600 ml/d), and in 14 within ﬁrst 4 days with persistent minor
(<200 ml/d) hemoptysis.20 The bleeding area was localized in all
patients prior to surgery by ﬁberoptic or rigid bronchoscopy.
Pneumonectomy was undertaken in 4 patients due to destroyed
lung, lobectomy was performed in 39 patients with cavitary lesions
occupying the lobe, segmentectomy or wedge resection was
performed in 16 patients due to cavitary lesion occupying one or
more segments. Twenty of those patients were receiving anti-TB
treatment and remaining 39 were asymptomatic with no current
anti-TB medications even though they had irregular previous
treatment history. Fifty one of 59 had AFB from cavitary lesion or
sputum cultures. In their experience, thoracotomy with double-
lumen endotracheal intubation and resection of cavity was
curative and lifesaving in TB-related hemoptysis with only <7%perioperative mortality which included single-lumen endotrache-
al intubation.
Surgical therapy has been quite extensively pursued in the
management of chronic pulmonary TB patients in Russia.21,22
Report with results from 109 patients (56 newly diagnosed TB and
53 retreatment cases) treated with artiﬁcial pneumothorax applied
for average period of 4.5 months in the ﬁrst group and for 9 months
in the second group respectively, showed 100% clinical improve-
ment in all new cases and 81% culture negativity in the retreatment
cases. 80% of these cases had DR-TB.
A South Korean study addressing surgical intervention for
M/XDR-TB in 72 patients during the period of 1996 to 2008 in-
cluded 26 patients with XDR-TB and reported with 90% favourable
outcome following surgical resection.23 The indications for surgery
were failure of medical treatment (71%), localized disease or
persistent cavity with high probability of relapse (24%) and
combined complication of hemoptysis (5%). The majority of patients
(81%) were culture positive. A lobectomy was performed in 53% of
patients with or without segmentectomy or wedge resection, 32%
had pneumonectomies, 14% had segmentectomies and only 1 out of
72 had multiple wedge resections. There were 11% post-operative
complications. Adjunct surgical therapy with adequate chemother-
apy was proposed to achieve high cure rated and to preserve lung
parenchyma for selected patients of M/XDR-TB.
As massive hemoptysis is a life-threatening condition, lung
resection is curative and bronchial artery embolization has high
recurrence rates, we would recommend that lung resection is the
primary modality of treatment of this group of patients.19 Patients
with localized disease are assessed for suitability concerning lung
resection using standard medical treatment options, including a
6 minute walk test, Karnovsky score, arterial blood gas on room air
and pulmonary function tests.
Figure 1 shows a High Resolution CT Scan (HRCT) from a 40 year
old patient treated at our Cardiothoracic Unit who presented with
massive hemoptysis. The HRCT Scan of the chest showed
bronchiectasis and cavitation in the right lung, the patient was
treated with bronchial artery embolization and then underwent a
right pneumonectomy. Our recommendation is that for patients
with massive hemoptysis, with cavitary lung disease and/or
bronchiectasis and who are suitable for a lung resection that this
should be the deﬁnitive treatment modality.10 Bronchial artery
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that lung resection for massive hemoptysis is curative and can be
safely undertaken. In addition, as a basic surgical principle, there must
be irreversible pulmonary destruction,  cavitation and/or bronchiec-
tasis in order to offer surgical therapy. If there are reversible
pulmonary changes, e.g. consolidation and tuberculoma, then medical
treatment is the primary treatment. The failure of medical treatment,
e.g. persistent sputum positivity along with a large inﬂammatory
mass represents a clinical indication when lung resection can be
considered in order to decrease the burden of disease and allow better
access of the anti-TB drugs in order to be more effective. Thus, lung
resection for pulmonary TB has been performed in the past for TB -
prior to the availability of antibiotics for TB - and it has undergone a
full circle: it is now indicated for the treatment of DR-TB and failed
medical treatment in patients with localized disease.
6. Lung Resection in HIV Co-infected Patients
In medical patients with TB in Durban, 69.8% are HIV co-
infected.24 Patients who are HIV positive, we assess the CD4 count
and serum albumin levels. Patients who have a CD4 count <400/
mm3 are treated with ARVs for at least 3 months prior to surgery. If
their albumin levels are <30 g/dl, they are referred to the dietician
for nutritional supplementation until their albumin levels are
30 g/dl or higher prior to surgery. In patients on anti-retroviral
treatment, viral load level is also assessed. Only if the viral load is
undetectable, surgery is performed in our Cardiothoracic Unit.
Patients with detectable viral loads are referred back to the
infectious diseases physicians for review and modiﬁcation of their
ARVs regimen until it is undetectable, prior to surgery. We have
previously shown to achieve good results for cardiac surgical
procedures in HIV positive patients25 and similar measures can be
used to manage patients with Mtb-HIV co-infections.
In HIV positive patients that would require emergency lung
resection (usually massive hemoptysis), our approach is to assess
the patient on general grounds for suitability for lung resection,
effort tolerance before hemoptysis, nutritional status, stigmata of
AIDS and speciﬁc investigations include arterial blood gas and
albumin levels. Another group of patients that requires special
attention concerning lung resection are children with bronchiec-
tasis secondary to pulmonary TB. These patients usually present
with a history of recurrent chest infections, hemoptysis, persistent
sputum positive state or empyema. We have previously shown
that pneumonectomy can be safely undertaken in children.26 In the
intra-operative management of these patients, lung isolation and
prevention of contamination of the opposite lung with Mtb positive
tissue can be challenging. We use double-lumen tubes to isolate
the lung in older children and a bronchus blocker and/or
positioning when it is not possible to place a double lumen tube.
The extent of lung resection is usually the equivalent of one lung.
Bilateral lung operations in our practice have been staged upper
lobectomies for hemoptysis or DR-TB. We have occasionally
undertaken a left pneumonectomy and subsequently a tightly
shrunken, bronchiectatic right upper lobe resected for the manage-
ment of symptom recurrence. The dilemmas arise in patients with
scattered bronchiectasis, bronchiectasis in un-shrunken lung and
patients warranting upper lobectomy, with middle lobectomy on
the right in the presence of apical lower segmental bronchiectasis.
The surgical options are pneumonectomy, apical lower segmental
resection with/without thoracomyoplasty.
7. Preparation of Patients for Lung Resection
As in any patient undergoing a major thoracic surgical
procedure, the pre-operative preparations of these patients are
critical for ensuring a good outcome. We ensure at least 3-6months of TB treatment before surgery. Patients with hemoptysis
or recurrent chest infections are also treated with appropriate
antibiotics if an organism is isolated or if sputum cultures are
negative or in emergency surgery with empiric triple antibiotics.
The crucial role of the physiotherapist cannot be emphasized
enough in the pre-operative preparation and post-operative care of
these patients to ensure a successful outcome.27
Preoperative physiotherapy, pulmonary function testing, arte-
rial blood gas on room air and a six minute walk testing are
undertaken. Use of bronchodilators in patients with a history of
smoking or evidence of bronchospasm on pulmonary function
testing is also essential. We undertake a bronchoscopy in the
preoperative workup of the patient. This is for ‘air-way toilet’ and
serves at the same time to sample specimens for microbiological
testing. This is repeated at weekly intervals, until the airways are
clear. This may not be always possible, for instance, if the surgeon
undertakes lung resection in the presence of scattered upper lobar
bronchiectasis and lower lobe bronchiectasis. The aim would be
here to remove the bronchiectatic lower lobe that would bring
about amelioration of the symptoms associated with recurrent
chest infections. When operating thorough an empyema space, a
pus swab is taken about 72 hours preoperatively and these
patients receive the appropriate antibiotics peri-operatively. If
there is minimal drainage from the empyema space, lung resection
is only planned weeks/months later, then the intercostal drainage
(ICD) is removed and the wound is allowed to close. This allows the
possibility of operating through a ‘‘clean’’ ﬁeld, since drains are
potentially two–way streets for infective organisms. Intra-opera-
tive management would include lung isolation with a double
lumen tube or a bronchus blocker, meticulous hemostasis and a
thoracic epidural for intraoperative and post-operative analgesia.
Post-operatively patients are usually extubated and managed in an
intensive care ward.
8. Novel method of managing a chronic TB associated empyema
thoracis
A chronic TB empyema space requires excellent drainage.
Methods of drainage include ICD, rib-resection if not amenable to
ICD, and ambulatory drainage (Figure 2 and 3). An ambulatory
drain is used in our patients with a chronic empyema with a non-
pliable cortex covering the lung until completion of TB treatment
and in patients with a chronic empyema not amenable to deﬁnitive
surgery.
This is determined by comparing the chest radiography with
the ICD connected to an underwater drain, with a chest radiograph
with the ICD open to air. If the lung does not collapse upon opening
the ICD to air, this indicates that the cortex covering the lung is
non-pliable and the ICD is converted to an ambulatory drain. The
self-retaining intercostal drain is cut about 5 cm from the skin, a
sterile safety-pin is passed through the cut drain to prevent it
falling into the empyema space and the drain is allowed to drain
into a colostomy bag (Figures 2). This allows patients greater
mobility, without being tethered to an underwater drain; patients
can also be treated this way in an outpatient setting. This is also an
important modality of treatment in patients with an empyema, not
amenable to deﬁnitive surgical intervention, e.g. lung resection. It
is also suitable to use in patients with thick pus, since there are no
valves in the system that can be occluded (by pus). Post-
pneumonectomy empyema is a dreaded complication after lung
resection. It is especially common after trans-empyema pneumo-
nectomies. In our practice, it occurs in 44% of trans-empyema
pneumonectomies. The key to drainage of an empyema is
dependent drainage. If a plain antero-posterior (AP) and lateral
chest radiograph is not helpful, we use a two view sinogram, and
AP and lateral chest radiograph with contrast instilled through the
Figure 2. Patient with an ambulatory drain in situ, secured with a safety pin. The colostomy bag has been removed for better visualization.
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empyema space.
9. Less common indications for thoracic surgical interventions
in TB:
1. In 1997, Hewitson, et al28 described lymph node (LN) evacuation
for airways compression in 36 patients from a total of
161 children that underwent 168 therapeutic surgical inter-
ventions. These patients had airway compression and im-
pairment that did not respond to high dose corticosteroids. Of
note, Hewitson stated that the LN should not be excised, just
evacuated as the nodes are densely adherent to the airways.
Figure 3 shows the typical CT scan of a 4 year old child with TB
lymphadenitis. The lymph nodes typically show ring enhance-
ment with central breakdown. In our Cardiothoracic unit, about
40 lung resections/year are being undertaken for children for
pulmonary TB; yet there was until now no clinical need for theFigure 3. TB lymphadenitis. A CT Scan with contrast showing multiple mediastinal
TB lymph nodes with typical central breakdown.selective LN evacuation procedure. This patient was managed
successfully with TB treatment and steroids.
2. Cavernostomy is an uncommon procedure indicated for patients
with massive hemoptysis who are not candidates for lung
resection.29,30 Bronchial artery embolization is now also an
option, although it is less successful long term in patients with
cavitary lung disease and bronchiectasis, the pathologies most
common in patients with hemoptysis secondary to TB.10,19 We
would therefore strongly recommend that patients with
massive hemoptysis should be seen by a joint thoracic surgical,
pulmonologist and interventional radiology team to decide on
the best treatment strategy.
3. Thorocoplasty is a cosmetically unappealing procedure under-
taken to collapse the chest wall onto the lung during partial lung
resection and the remaining lung is deemed unlikely to ﬁll the
pleural space,29 as well as for the treatment of a post-
pneumonectomy empyema. It may also be undertaken as a
secondary procedure (for the same indication) or for patients
with chronic pleuro-pulmonary suppuration not amenable to
decortication, nor for lung resection.31,32 More commonly, this
procedure is undertaken for the treatment of a post-pneumonec-
tomy empyema; it is important to close the broncho-pleural
ﬁstula, if present. Myoplasty without thoracoplasty is preferred.
However, a large number of patients in need a thoraco-myoplasty
are malnourished and lack the muscle mass for a myoplasty.
Therefore, a thoracoplasty in our Cardiothoracic Unit is the
procedure most frequently performed. Surgery through progres-
sively smaller incisions and Video Assisted Thoracic Surgery (VATS)
has become increasingly frequent. Generally, lung resection for TB
complications does not represent a good case for video-assisted
surgery. In the majority of these patients, the lung is ﬁrmly
attached to the chest wall and has to be carved using cautery and
careful hemostasis. Predictors of unsuitability for VATS lung
resection are multiple cavities, multi-lobar tuberculoma, extensive
pleural thickening and peribronchial lymph node calciﬁcation.33
We had to occasionally perform a posterior rib osteotomy to get
adequate exposure in order to safely mobilize the lung.
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insights
Lung resection in the setting of active TB, DR-TB and HIV co-
infection provides exciting prospects for collaboration between
thoracic surgeons and laboratory scientists undertaking TB
research to decipher the pathophysiology of TB granuloma. This
collaboration may also aid to design more effective intervention(s)
targeting lung tissue. While the animal models have been a major
endeavor in the development of drugs and vaccines, it is well
known that there is lack of central caseous necrosis in the murine
lung granuloma,34 the TB–associated pathology is different than
those seen in human patients. Differences in TB pathophysiology
between mice and humans may be one of the many reasons for
failures in translation of novel TB vaccines and TB drugs. Access to
surgical pulmonary tissues may aid to elucidate the mechanisms of
lung destruction and cavitation in TB, it may also represent a
unique opportunity to work in a symbiotic collaborative interdis-
ciplinary approach between clinicians and clinical researchers. The
clinically impressive data after surgical pulmonary resections may
also encourage are more detailed immunological evaluation of the
role of high antigenic (bacterial) burden and its role on expanding
anti-M.tb directed immune responses, particularly in the case of
DR-TB. It is also reasonable to speculate that surgical resection
options should be discussed as an option in combination with
drug-therapy as well as with any emerging novel therapies which
would curtail the period of treatment and to achieve cure or non-
infectivity in a shorter time frame.
11. Discussion
There is renewed interest in the surgical treatment of
complicated pulmonary TB, including DR-TB. Surgery has been
shown to be safe and in the presence of localized cavitary or
bronchiectatic disease, lung resection is potentially curative.
Massive hemoptysis may be a life-threatening complication of
TB. While bronchial artery embolization is able to stop hemoptysis
in up to 90% of cases, recurrence of hemoptysis is frequent in the
presence of bronchiectasis and cavitary lung disease. This
experience has guided our thoracic surgical unit’s practice to
prioritize lung resection as the primary treatment option in such
patients. The indications for surgery in patients with TB are
recurrent chest infections, recurrent minor hemoptysis, massive
hemoptysis, DR-TB and the complications of TB such as empyema
thoracis. Lung resection can also safely be undertaken in reasonably
immunocompetent HIV co-infected patients. A novel technique
(ambulatory drain) for the management of a chronic empyema
thoracis is also described.
Observational studies with surgical interventions have
shown a high treatment success rate when used as adjunctive
therapy in M/XDR-TB patients, however there has been lack of
randomized controlled trials of surgical resections. In many
cases of complicated M/XDR-TB with localized lesions and tissue
destruction along with failure to become culture negative,
adjunctive surgical therapy may play a major role in improving
clinical outcome. Collaboration and synergy between clinicians
(from various disciplines) and basic scientists is critical for
making tangible progress toward achieving control of the
TB epidemic.
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